Product Description
Modithromycin and EDP-322 could be effective options for treatment of gonorrhoea, particularly for cases resistant to extended-spectrum cephalosporins and as a part of an antimicrobial combination therapy regimen.
Mechanisms of Action: Gram+ Inhibitor
Novel Mechanism: Yes
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Enanta
Company Location: Eastern America
Company CEO: Jay R. Luly
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers|Soft Tissue Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00990145 |
EDP-322-07-002 | P1 |
Completed |
Healthy Volunteers |
2009-03-01 |
2022-09-20 |
Primary Endpoints|Treatments |
|
NCT00989872 |
EDP-322-007-001 | P1 |
Completed |
Soft Tissue Infections |
None |
2022-09-20 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|